Investigations

1st investigations to order

Test
Result
Test

Allows for the accurate determination of biventricular systolic and diastolic function. With systolic heart failure, echo usually demonstrates a dilated left and/or right ventricle with low ejection fraction. With pure diastolic heart failure left ventricular ejection fraction (LVEF) is normal but there is evidence of left ventricular hypertrophy (LVH) and of abnormal diastolic filling patterns on Doppler evaluation. Echo can also identify valvular or pericardial disease or may reveal evidence of underlying coronary artery disease (regional wall motion/thickness abnormalities). It should be performed in every patient presenting with heart failure symptoms.

Result

systolic heart failure: depressed and dilated left and/or right ventricle with low ejection fraction; diastolic heart failure: LVEF normal but LVH and abnormal diastolic filling patterns

Test
Result
Test

QRS duration greater than 120 ms should always raise the question of ventricular dyssynchrony.

Result

evidence of underlying coronary artery disease, left ventricular hypertrophy, or atrial enlargement; may be conduction abnormalities and abnormal QRS duration

Test
Result
Test

May reveal pulmonary vascular congestion (vascular redistribution, Kerley B lines), cardiomegaly (increased cardiothoracic ratio), or pleural effusion (usually right-sided but often bilateral).

Result

abnormal

Test
Result
Test

Elevated plasma BNP levels have been associated with reduced left ventricular ejection fraction,[71] left ventricular hypertrophy, elevated left ventricular filling pressures, and acute myocardial infarction and ischemia, although they can occur in other settings, such as pulmonary embolism and chronic obstructive pulmonary disease.[71][72][73] They are sensitive to other biologic factors, such as age, sex, weight, and renal function. Elevated levels lend support to a diagnosis of abnormal ventricular function or hemodynamics causing symptomatic heart failure.[74][75][76] A low plasma BNP level (<100 picograms/mL) can rapidly rule out decompensated heart failure and point to a pulmonary cause. A high plasma BNP level (>400 picograms/mL) strongly supports the diagnosis of abnormal ventricular function (i.e., heart failure). Intermediate values (100 to 400 picograms/mL) fall into the so-called "gray zone" and should spur a search for a potential noncardiac cause of dyspnea: for example, COPD. In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclude heart failure. However, elevated plasma levels of natriuretic peptides can occur with a wide variety of cardiac and noncardiac causes; therefore, clinical judgment is necessary.[70]

Trials with this diagnostic marker suggest that its use may reduce both the time to hospital discharge and the cost of treatment.[77][78][79] B-type natriuretic peptide levels tend to be less elevated in heart failure with preserved ejection fraction than in heart failure with low ejection fraction and are lower in obese patients.[80] Levels of BNP may be elevated meaningfully in women and in people over 60 years of age who do not have heart failure, and thus BNP levels should be interpreted cautiously in such individuals.[61][81][82]

Result

elevated

Test
Result
Test

Anemia and high lymphocyte percentage are strong risk factors and prognostic markers of poor survival.

Result

laboratory testing may reveal important heart failure etiologies, the presence of disorders or conditions that can lead to or exacerbate heart failure; laboratory testing could also reveal important modulators of therapy

Test
Result
Test

Baseline electrolytes should be obtained in all patients.

Result

decreased sodium (usually <135 mg/dL), altered potassium

Test
Result
Test

Reflects tissue perfusion, fluid status, rules out renal disease.

Result

normal to elevated

Test
Result
Test

Screening for diabetes mellitus as a comorbid condition. Diabetes mellitus has been associated with a 3- to 5-fold increase in the risk of developing heart failure.[10][11][12][14][15][16]

Result

elevated in diabetes

Test
Result
Test

Reflects abdominal congestion.

Result

normal to elevated

Test
Result
Test

Screening for hypo- or hyperthyroidism. Both can be a primary or contributory cause of heart failure.

Result

primary hypothyroidism: elevated TSH, decreased free thyroxine (FT4); hyperthyroidism: decreased TSH, elevated free triiodothyronine, elevated FT4

Test
Result
Test

Screening for dyslipoproteinemias/metabolic syndrome.

Result

elevated in dyslipidemia, decreased in end-stage heart failure, especially in the presence of cardiac cachexia

Test
Result
Test

For evaluation of cardiomyopathy due to iron overload cardiomyopathy/hemochromatosis.

Result

elevated (normal value 10-200 nanograms/mL)

Test
Result
Test

For evaluation of cardiomyopathy due to iron overload cardiomyopathy/hemochromatosis.

Result

elevated level of transferrin saturation; complete or almost complete transferrin saturation (normal transferrin saturation 22% to 46%)

Investigations to consider

Test
Result
Test

Provides an objective assessment of the patient's functional exercise limitation and hemodynamic response to exercise. Test is ordered when exercise-induced arrhythmias or ischemia are suspected. Caution should be taken if there is a high likelihood for aortic stenosis or hypertrophic obstructive cardiomyopathy.

Result

usually reduced exercise capacity in idiopathic dilated cardiomyopathy; reduced exercise capacity and signs of impaired myocardial perfusion in ischemic cardiomyopathy; however, functional capacity may be completely normal in patients with low left ventricular systolic function.

Test
Result
Test

Provides the most objective assessment of the patient's functional status.

Result

reduced VO₂ max

Test
Result
Test

A patient with heart failure who cannot walk more than 300 m in 6 minutes has a substantially greater annual risk of death than one who can walk 450 m or more.

Result

as an alternative to cardiopulmonary exercise testing it may provide an objective assessment of the patient's functional status

Test
Result
Test

Considered in patients intolerant to standard medical therapy, in whom medical therapy has failed to achieve symptomatic relief, before initiation of IV inotrope or inodilator therapy and in candidates for heart transplantation.

Result

provides objective hemodynamic assessment of left ventricular filling pressure and direct measures of cardiac output and pulmonary and systemic resistance

Test
Result
Test

Ordered if acute myocarditis (giant cell or eosinophilic) or primary infiltrative diseases of the heart (amyloidosis, active cardiac sarcoidosis) suspected.

Result

rarely necessary to establish the etiology of heart failure; provides definitive pathologic evidence of cardiac and systemic disease

Test
Result
Test

The majority of patients who have cardiomyopathy due to HIV do not present with symptoms of heart failure until other clinical signs of HIV infection are apparent.

Result

positive or negative

Test
Result
Test

Particularly useful in evaluation of conditions like myocarditis, constrictive pericarditis, and infiltrative cardiomyopathy.

Result

myocarditis: subepicardial delayed enhancement in myocardium, high signal in myocardium in T2-weighted imaging; infiltrative cardiomyopathy: amyloid (global subendocardial delayed enhancement); sarcoid (delayed enhancement); no subendocardial delayed enhancement; constrictive pericarditis: thick pericardium as well as diastolic septal bounce with inspiration

Emerging tests

Test
Result
Test

Troponin is helpful in further risk stratification in chronic heart failure, as elevated level is associated with progressive left ventricular dysfunction and increased mortality.[2]

Soluble ST2 and galectin-3 (biomarkers for myocardial fibrosis) are predictive of death and hospitalization in patients with heart failure and are additive to natriuretic peptide in their prognostic value.[2]

Result

borderline to minimally elevated

Test
Result
Test

A new method for left ventricular ejection fraction (LVEF) estimation. There appears to be no significant difference in LVEF estimation between MSCT and MRI, and also between MSCT and transthoracic echocardiogram.[83]

May offer additional benefit as it provides a combined evaluation of LVEF and coronary artery disease.

Result

quantifies LVEF and coronary artery disease

Use of this content is subject to our disclaimer